RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE ONLY
This article is only for trained researchers working in controlled in-vitro experiments or published laboratory-animal studies. Personal or home handling is prohibited.
The materials discussed are not intended, manufactured, tested, or released for human administration, veterinary administration, diagnosis, treatment, cosmetic use, or any other non-research purpose. Any information about concentration, timing, reconstitution, storage, or handling is laboratory information only and must not be read as a dosing or administration guide.
Modified GRF(1-29)—commonly marketed as CJC-1295 No DAC—and ipamorelin are two synthetic research peptides linked to different receptor pathways in pituitary research. Modified GRF(1-29) has the formal designation [D-Ala2,Gln8,Ala15,Leu27]-hGRF(1-29)-NH2 and acts through the growth hormone-releasing hormone receptor (GHRHR).

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts through the growth hormone secretagogue receptor (GHS-R1a). Studying them together is scientifically reasonable because earlier cell studies found that a growth hormone-releasing factor and a growth hormone secretagogue could produce a larger response together than either one alone.
However, those studies did not test this exact combination—they used GHRP-6 or GHRP-2 with native GRF. The modified GRF(1-29)–ipamorelin pair should therefore be described as a research hypothesis that needs direct testing, not as a proven synergistic blend.
Chemical identity
In this article, modified GRF(1-29) (commercially referred to as CJC-1295 No DAC) means the amidated 29-amino-acid peptide Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. Its four changes from native hGRF(1-29) are D-Ala2, Gln8, Ala15, and Leu27.
PubChem (CID 56841945) lists the molecular formula as C152H252N44O42, the average molecular weight as approximately 3,367.9 g/mol, and the monoisotopic mass as 3,365.8936 Da.[1]
The original long-acting CJC-1295 described by Jetté et al. (2005) is not the same structure as the No-DAC 29-mer. The original DAC form (CAS 446262-90-4) contains an added lysine residue carrying a maleimidopropionyl group that can form a covalent bond with Cys34 of serum albumin upon exposure to albumin-containing media, yielding a conjugate of approximately 67 kDa.
The DAC form in the vial is not itself a preformed albumin conjugate—it is approximately 3.65 kDa before exposure to albumin. The No-DAC form lacks the maleimide-functionalized lysine entirely and cannot form this albumin linkage.[2]
A legacy PubChem substance record (SID 319401640) links CAS 863288-34-0 to the broader CJC-1295 name. This CAS number has historically been associated with both DAC and No-DAC forms in various databases and should not be relied upon alone.
The formal DAC form carries CAS 446262-90-4 in current FDA G-SRS and PubChem records. Because DAC and No-DAC structures are different, a CAS number by itself is not enough to confirm which material is present.
The full sequence, terminal modification, molecular mass, and lot-specific analytical data should be checked together.[3]
Ipamorelin is the amidated pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2. PubChem (CID 9831659) lists its molecular formula as C38H49N9O5, its average molecular weight as approximately 711.9 g/mol, its monoisotopic mass as 711.3857 Da, and its CAS number as 170851-70-4.[4]
In the original study, ipamorelin released growth hormone from primary rat pituitary cells (EC50 1.3 ± 0.4 nmol/L, Emax 85 ± 5% relative to GHRP-6) and in rat and swine models through a GHS-R1a pathway. Unlike GHRP-6 and GHRP-2, ipamorelin did not produce ACTH or cortisol levels significantly different from GHRH stimulation, even at doses more than 200-fold above its GH ED50.[5]
| Item | Modified GRF(1-29) / CJC-1295 No DAC | Ipamorelin |
|---|---|---|
| Length | 29 amino acids, C-terminal amide | 5 amino acids, C-terminal amide |
| Main sequence features | D-Ala2, Gln8, Ala15, Leu27 | Aib1, D-2-Nal3, D-Phe4 |
| Molecular formula (free peptide) | C152H252N44O42 | C38H49N9O5 |
| Average molecular weight (free peptide) | Approximately 3,367.9 g/mol | Approximately 711.9 g/mol |
| Monoisotopic mass (free peptide) | 3,365.8936 Da[1] | 711.3857 Da[4] |
| CAS note | 863288-34-0 (legacy CJC-1295 record); DAC form: 446262-90-4. Confirm structure by sequence and LC-MS. | 170851-70-4 |
| Main research receptor | Growth hormone-releasing hormone receptor (GHRHR) | Growth hormone secretagogue receptor (GHS-R1a) |
What the combination can be used to study
The GHRH receptor is a G-protein-coupled receptor. In receptor-expression studies, GHRH binding increased intracellular cAMP.[6]
The growth hormone secretagogue receptor is a separate receptor found in pituitary and hypothalamic research models and is activated by growth hormone secretagogues.[7]
In primary rat pituitary cells, GHRP-6 (EC50 approximately 7 × 10−9 M) and GRF produced a larger growth hormone response together than either compound alone. The same study found that GHRP-6 enhanced the cAMP response produced by GRF, while GHRP-6 alone did not raise intracellular cAMP.[8]
A separate study showed that the response to GHRP compounds can change with the ligand and animal species—GHRP-6 and GHRP-2 produced different cAMP and GH secretion responses in ovine and rat somatotrophs.[9]
These studies explain why researchers may test modified GRF(1-29) and ipamorelin together, but they do not prove that this exact pair will always be additive or synergistic. Results from GHRP-6, GHRP-2, ghrelin, or a different GHRH analog should not be presented as direct evidence for this blend.
Basic in-vitro study design
Laboratory-only note: This section covers in-vitro assay design only. It is not a human or veterinary dosing, timing, or administration guide.
A basic comparison should include a vehicle control, modified GRF(1-29) alone, ipamorelin alone, and the two peptides together. A suitable positive control or receptor-blocking control may also be added.
Concentrations and exposure times should come from a small pilot study in the exact cell model being used, not from unrelated animal or pharmacokinetic data.
Possible readouts include cAMP, intracellular calcium, selected signaling markers, and growth hormone released into the culture medium. The readout must match the cell model: cAMP and calcium signaling can be measured in receptor-expressing cell lines, while GH secretion requires a suitable pituitary-cell or somatotroph model.
A concentration range and more than one time point are more useful than a single test condition. For rigorous synergy evaluation, full concentration-response curves for each peptide alone and a two-dimensional concentration matrix of the combination should be used rather than a single fixed ratio.
A claim of synergy should be based on a stated additivity model (e.g., Bliss independence or Loewe additivity), a defined calculation method, and repeated independent biological experiments.
Results may change because of cell source, species, receptor level, passage number, serum conditions, peptide loss on plastic surfaces, sample degradation, counterion content, or an incorrect blend ratio. These details should be recorded when the experiment is reported.
Blend ratio specification
Because modified GRF(1-29) (~3,367.9 g/mol) and ipamorelin (~711.9 g/mol) differ in molecular weight by approximately 4.7-fold, specifying the blend ratio as “1:1” without stating whether it refers to mass or molar basis is ambiguous. A 1:1 mass ratio corresponds to an approximately 1:4.7 molar ratio, while a 1:1 molar ratio requires an approximately 4.7:1 mass ratio.
The blend specification should state:
- The target ratio expressed as mass:mass or mol:mol, calculated on an anhydrous, counterion-free peptide basis;
- The allowed tolerance range for the ratio;
- The nominal content of each peptide per vial or unit;
- Vial-to-vial content uniformity;
- The quantitative method used for each peptide (independently calibrated against appropriate reference standards), since the two peptides have different UV absorbance, ionization efficiency, and chromatographic response.
How to read the COA
A COA should separate three different questions: Is it the correct peptide? How much chromatographic impurity is present? and How much peptide is actually in the sample? These are not the same measurement.
ICH Q6A is a regulatory quality guideline cited here as a general framework; its basic identification rule is useful: one HPLC retention time alone is not specific enough for identity. A combination such as HPLC with mass spectrometry gives stronger identity evidence.[10]
The analytical method should also be shown to work for its intended purpose, following the general validation principles in ICH Q2(R2), cited here as an analytical framework and not as a regulatory specification for this research-use-only material.[11]
| COA item | What should be shown | What the result does not prove |
|---|---|---|
| Identity | Full sequence, D-amino acids or other non-standard residues, C-terminal amide, DAC status, and counterion or salt form. At least two orthogonal methods are recommended (e.g., LC-MS plus MS/MS or peptide mapping). | A product name or CAS number alone does not confirm the exact structure. Intact mass alone cannot distinguish D/L configuration, Leu/Ile isomers, or confirm the attachment site of modifications. |
| LC-MS / HRMS | Theoretical monoisotopic neutral mass (modified GRF(1-29): 3,365.8936 Da), expected charge-state ions (e.g., [M+3H]3+ m/z 1,122.9718), instrument tolerance, deconvolution method, and any observed adducts. The average molecular weight of 3,367.9 g/mol should not be used as the direct high-resolution MS target. | For modified GRF(1-29), 3,367.9 Da is the average molecular weight; it is not the m/z of any specific charge state and should not be used for HRMS identity matching |
| RP-HPLC purity | Column, mobile phases, gradient, detection wavelength, integration rules, and area-percent result. Individual impurity peaks above a specified threshold should be reported. | HPLC area purity does not confirm the sequence, does not equal peptide content, and may not detect co-eluting impurities, non-UV-absorbing species, or peptide aggregates |
| Peptide content / assay | A quantitative assay (e.g., amino acid analysis, calibrated quantitative HPLC, or qNMR) that accounts for water, counterions, salts, and other non-peptide material. The reporting basis (as-is, anhydrous, counterion-free, or free-peptide-equivalent) must be stated. | The total powder weight in a vial is not automatically the net peptide weight |
| Peptide-related impurities | Deletion sequences, truncated sequences, insertion sequences, epimers/diastereomers, oxidized forms, and deamidated or hydrolyzed products. For this blend, impurities that co-elute or overlap between the two peptides should be assessed. | A single total-purity percentage does not identify or quantify individual high-risk impurities |
| Counterion and residual TFA | Identity and quantitative content of acetate, TFA, chloride, or other counterions. The counterion content should be used in peptide-content calculations. | Counterion content must be accounted for; ignoring it produces incorrect molar calculations |
| Aggregates / oligomers | Aggregate content measured by an orthogonal method such as size-exclusion chromatography when relevant to the assay | Conventional RP-HPLC may not adequately separate or detect peptide aggregates |
| Blend ratio | Separate identification and quantitation of both peptides against independently calibrated reference standards, with a stated target ratio (mass or molar), an allowed tolerance range, and vial-to-vial uniformity data | Raw MS signal intensity or total HPLC area ratio should not be used as an unvalidated blend-ratio result; the two peptides have different UV absorbance, ionization efficiency, and chromatographic response |
| Water and residual solvents | A stated method, reporting limit, and lot result for relevant solvents and water | “Solvent free” is not meaningful without a method and detection limit |
| Model-specific tests | Endotoxin, bioburden, or sterility-related testing only when needed for the planned laboratory model | HPLC and LC-MS do not prove sterility or low endotoxin |
Do not state a purity such as “≥95%” or “≥98%” unless the lot COA gives that result and explains the HPLC method. Residual-solvent testing should cover solvents that may remain from synthesis, cleavage, purification, or drying.
ICH Q3C(R9) provides a recognized framework for residual-solvent classification and control, cited here as a general reference; the COA still needs to show the actual method and lot result.[12]
Reconstitution, storage, and handling
STRICT LABORATORY-ONLY HANDLING NOTICE: Reconstitution and aliquoting must be done by trained laboratory staff with calibrated laboratory pipettes. Personal or home preparation is prohibited.
This article does not provide syringe-based or injection-solution preparation steps.
There is no single solvent or concentration that is correct for every lot and every assay. Solubility can change with peptide concentration, pH, counterion, container material, and the method being used.
Start with the lot-specific information. If that information is not available, run a small laboratory solubility test before preparing the full sample.
Water or dilute aqueous acid may be tested as laboratory solvents, but neither should be described as a universal choice. When using dilute acid, the acid type, pH, and compatibility with the assay must be stated and recorded.
Let a sealed frozen vial reach the laboratory working temperature before opening it, so moisture does not condense inside. Add solvent with a calibrated pipette, mix gently, and check for particles or incomplete dissolution.
A sterile starting solvent does not make the final solution sterile.
Common research storage conditions for lyophilized peptides include 2–8°C or approximately −20°C; the specific temperature, retest period, and allowable short-term temperature excursions must be determined from batch-specific stability and packaging compatibility data.
In the absence of such data, −20°C with protection from light and moisture may be used as a conservative temporary holding condition, not as a validated shelf-life claim.
The usable life of a reconstituted solution, its storage temperature, and the allowed number of freeze-thaw cycles must come from stability data. Storage and retest periods should not be claimed without supporting stability results.
ICH Q1A(R2) is cited here as a general stability framework only.[13]
If frozen storage of the prepared laboratory solution is supported by the available stability data, divide it into small aliquots to reduce repeated freeze-thaw cycles. Record the solvent, pH, nominal concentration, container type, preparation date, storage condition, and freeze-thaw history.
Authoritative sources
- PubChem. CID 56841945: modified GRF(1-29) (CJC-1295 No DAC) sequence, formula, molecular weight, and monoisotopic mass. PubChem CID 56841945.
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PubMed 15817669.
- PubChem. SID 319401640: legacy CJC-1295 substance record (historical CAS 863288-34-0). PubChem SID 319401640.
- PubChem. CID 9831659: ipamorelin sequence, formula, molecular weight, monoisotopic mass, and CAS number. PubChem CID 9831659.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PubMed 9849822.
- Gaylinn BD, Harrison JK, Zysk JR, Lyons CE, Lynch KR, Thorner MO. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Molecular Endocrinology. 1993;7(1):77-84. doi:10.1210/mend.7.1.7680413. PubMed 7680413.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PubMed 8688086.
- Cheng K, Chan WW, Barreto A Jr, Convey EM, Smith RG. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone-releasing factor-stimulated GH release and intracellular cyclic adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology. 1989;124(6):2791-2798. doi:10.1210/endo-124-6-2791. PubMed 2541999.
- Wu D, Chen C, Zhang J, Bowers CY, Clarke IJ. The effects of GHRP-6 and GHRP-2 on intracellular cAMP levels and growth hormone secretion in ovine and rat somatotrophs. Journal of Endocrinology. 1996;148(2):197-205. doi:10.1677/joe.0.1480197. PubMed 8699133.
- U.S. Food and Drug Administration. ICH Q6A: Specifications—Test Procedures and Acceptance Criteria. FDA Q6A.
- U.S. Food and Drug Administration. ICH Q2(R2): Validation of Analytical Procedures. FDA Q2(R2).
- U.S. Food and Drug Administration. ICH Q3C(R9): Impurities—Residual Solvents. FDA Q3C(R9).
- U.S. Food and Drug Administration. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. FDA Q1A(R2).
Research Use Only Disclaimer
Research Use Only: All SaiyanMed products are intended and labeled solely for laboratory research use. They are not intended, manufactured, tested, or released for human or veterinary administration.
This article provides general scientific information regarding standard laboratory in vitro and in vivo research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.